Redefining the future of antibody discovery with LiteMab Antibody Discovery Studio

Designed to accelerate and empower therapeutic innovation, Mabqi unveils its LiteMab© Antibody Discovery Studio which brings together complementary and fully integrated platforms:

• LiteMab© – Powered by proprietary, high-diversity and fully human antibody libraries spanning broad structural and paratope landscapes to enable unprecedented discovery space. Our core platform is focused on discovery of classical antibodies including complex and difficult targets such as GPCR, ion channels, …
• LiteMab© Sense – Focused on conditionally active, pH-sensitive antibodies, leveraging a proprietary antibody library and a tailored screening workflow.
• LiteMab© Neo for next-generation biologics – A specific approach for maturation of parental antibodies and in vitro selection tools enabling precise tuning of affinity, pH sensitivity, and functional activity while preserving developability.

LiteMab Antibody Discovery Studio is more than a suite of platforms— it’s a collaborative framework where science and partnership meet.